Metraipolis › archive › dc_aa7a30ffa242

Real-World Outcomes of Polatuzumab Vedotin Plus R-CHP Versus R-CHOP-Based Regimens in Japanese Patients With Untreated Diffuse Large B-Cell Lymphoma — Europe PMC PMID:41521802

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41521802
DOI
10.1002/cam4.71531
License (as archived)
solo-consultazione
Archived
2026-11-07T05:44:04.455Z
SHA-256 of the archived text
644eb3f606787ef690ebb4330d80b9c6e25a16f5599caa108b0ed767331abba6
Stable URL of this page
https://metraipolis.com/documento/dc_aa7a30ffa242

How to cite

Real-World Outcomes of Polatuzumab Vedotin Plus R-CHP Versus R-CHOP-Based Regimens in Japanese Patients With Untreated Diffuse Large B-Cell Lymphoma — Europe PMC PMID:41521802 — Europe PMC (en), https://europepmc.org/article/MED/41521802 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_aa7a30ffa242 (Metraipolis archive dc_aa7a30ffa242, sha256 644eb3f606787ef690ebb4330d80b9c6e25a16f5599caa108b0ed767331abba6)
BibTeX
@misc{dcaa7a30ffa242,
  title = {Real-World Outcomes of Polatuzumab Vedotin Plus R-CHP Versus R-CHOP-Based Regimens in Japanese Patients With Untreated Diffuse Large B-Cell Lymphoma — Europe PMC PMID:41521802},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41521802},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_aa7a30ffa242; sha256 644eb3f606787ef690ebb4330d80b9c6e25a16f5599caa108b0ed767331abba6},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41521802. Agents can read the archived copy with the MCP tool read_document.